122 related articles for article (PubMed ID: 31063493)
1. An in vivo half-life extended prolactin receptor antagonist can prevent STAT5 phosphorylation.
Yu S; Alkharusi A; Norstedt G; Gräslund T
PLoS One; 2019; 14(5):e0215831. PubMed ID: 31063493
[TBL] [Abstract][Full Text] [Related]
2. Stimulation of prolactin receptor induces STAT-5 phosphorylation and cellular invasion in glioblastoma multiforme.
Alkharusi A; Yu S; Landázuri N; Zadjali F; Davodi B; Nyström T; Gräslund T; Rahbar A; Norstedt G
Oncotarget; 2016 Nov; 7(48):79572-79583. PubMed ID: 27788487
[TBL] [Abstract][Full Text] [Related]
3. Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A.
Langenheim JF; Chen WY
Breast Cancer Res Treat; 2005 Apr; 90(3):281-93. PubMed ID: 15830142
[TBL] [Abstract][Full Text] [Related]
4. JAK2/STAT5 Pathway Mediates Prolactin-Induced Apoptosis of Lactotropes.
de Dios N; Orrillo S; Irizarri M; Theas MS; Boutillon F; Candolfi M; Seilicovich A; Goffin V; Pisera D; Ferraris J
Neuroendocrinology; 2019; 108(2):84-97. PubMed ID: 30376668
[TBL] [Abstract][Full Text] [Related]
5. Prolactin signal transduction to milk protein genes: carboxy-terminal part of the prolactin receptor and its tyrosine phosphorylation are not obligatory for JAK2 and STAT5 activation.
Goupille O; Daniel N; Bignon C; Jolivet G; Djiane J
Mol Cell Endocrinol; 1997 Mar; 127(2):155-69. PubMed ID: 9099911
[TBL] [Abstract][Full Text] [Related]
6. Development of a novel ligand that activates JAK2/STAT5 signaling through a heterodimer of prolactin receptor and growth hormone receptor.
Langenheim JF; Chen WY
J Recept Signal Transduct Res; 2009; 29(2):107-12. PubMed ID: 19519175
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells.
Cataldo L; Chen NY; Yuan Q; Li W; Ramamoorthy P; Wagner TE; Sticca RP; Chen WY
Int J Oncol; 2000 Dec; 17(6):1179-85. PubMed ID: 11078803
[TBL] [Abstract][Full Text] [Related]
8. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
Beck MT; Chen NY; Franek KJ; Chen WY
Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
[TBL] [Abstract][Full Text] [Related]
9. Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment.
Yang N; Liu C; Peck AR; Girondo MA; Yanac AF; Tran TH; Utama FE; Tanaka T; Freydin B; Chervoneva I; Hyslop T; Kovatich AJ; Hooke JA; Shriver CD; Rui H
Breast Cancer Res; 2013; 15(5):R73. PubMed ID: 24004716
[TBL] [Abstract][Full Text] [Related]
10. Prolactin specifically activates signal transducer and activator of transcription 5b in neuroendocrine dopaminergic neurons.
Ma FY; Anderson GM; Gunn TD; Goffin V; Grattan DR; Bunn SJ
Endocrinology; 2005 Dec; 146(12):5112-9. PubMed ID: 16123156
[TBL] [Abstract][Full Text] [Related]
11. Alpha
Castillo LF; Rivero EM; Goffin V; Lüthy IA
Cell Signal; 2017 Jun; 34():76-85. PubMed ID: 28302567
[TBL] [Abstract][Full Text] [Related]
12. Human prolactin receptors are insensitive to mouse prolactin: implications for xenotransplant modeling of human breast cancer in mice.
Utama FE; LeBaron MJ; Neilson LM; Sultan AS; Parlow AF; Wagner KU; Rui H
J Endocrinol; 2006 Mar; 188(3):589-601. PubMed ID: 16522738
[TBL] [Abstract][Full Text] [Related]
13. Prolactin controls Na
Bollinger RJ; Ellis LV; Bossus MC; Tipsmark CK
Mol Cell Endocrinol; 2018 Dec; 477():163-171. PubMed ID: 29959978
[TBL] [Abstract][Full Text] [Related]
14. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
[TBL] [Abstract][Full Text] [Related]
15. An immunohistochemical approach to monitor the prolactin-induced activation of the JAK2/STAT5 pathway in pancreatic islets of Langerhans.
Brelje TC; Svensson AM; Stout LE; Bhagroo NV; Sorenson RL
J Histochem Cytochem; 2002 Mar; 50(3):365-83. PubMed ID: 11850439
[TBL] [Abstract][Full Text] [Related]
16. Improving the pharmacokinetics/pharmacodynamics of prolactin, GH, and their antagonists by fusion to a synthetic albumin-binding peptide.
Langenheim JF; Chen WY
J Endocrinol; 2009 Dec; 203(3):375-87. PubMed ID: 19770179
[TBL] [Abstract][Full Text] [Related]
17. Augmented Stat5 Signaling Bypasses Multiple Impediments to Lactogen-Mediated Proliferation in Human β-Cells.
Chen H; Kleinberger JW; Takane KK; Salim F; Fiaschi-Taesch N; Pappas K; Parsons R; Jiang J; Zhang Y; Liu H; Wang P; Bender AS; Frank SJ; Stewart AF
Diabetes; 2015 Nov; 64(11):3784-97. PubMed ID: 26159175
[TBL] [Abstract][Full Text] [Related]
18. Prolactin signalling in the mouse hypothalamus is primarily mediated by signal transducer and activator of transcription factor 5b but not 5a.
Yip SH; Eguchi R; Grattan DR; Bunn SJ
J Neuroendocrinol; 2012 Dec; 24(12):1484-91. PubMed ID: 22775396
[TBL] [Abstract][Full Text] [Related]
19. Convergence of signaling transduced by prolactin (PRL)/cytokine chimeric receptors on PRL-responsive gene transcription.
Ferrag F; Chiarenza A; Goffin V; Kelly PA
Mol Endocrinol; 1996 Apr; 10(4):451-60. PubMed ID: 8721989
[TBL] [Abstract][Full Text] [Related]
20. CIS1 interacts with the Y532 of the prolactin receptor and suppresses prolactin-dependent STAT5 activation.
Endo T; Sasaki A; Minoguchi M; Joo A; Yoshimura A
J Biochem; 2003 Jan; 133(1):109-13. PubMed ID: 12761205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
